WASHINGTON — Drug and device companies with manufacturing operations in Puerto Rico have told the American public that their plants are getting up and running again, but that does “not reveal the true scope of the challenge that we are facing,” Food and Drug Administration Commissioner Scott Gottlieb said in prepared congressional testimony made available Monday.

“We have surveyed firms and can anecdotally relate that reports of manufacturing running below 50 percent are common, with many firms operating around 20 percent capacity, and some even less,” Gottlieb’s remarks read. “We have found no firm operating above 70 percent of their normal operation.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy